What started out as a diabetes drug is now rippling into industries far beyond healthcare. Fast food chains, alcohol sales, apparel retailers, among others. And fewer than 1 in 10 patients who could benefit from a GLP-1 may even be taking one. And I don’t think GLP-1s will be an anomaly. The oral GLP-1s just launched this year. @novonordisk and @EliLillyandCo's most recent earnings revealed that ~80% of patients starting oral pill formulations are new to the drug class entirely. Oral delivery is expanding the user base, not cannibalizing injectable users. And the clinical reach keeps expanding well beyond diabetes — weight management, cardiovascular risk reduction, kidney disease, sleep apnea — establishing GLP-1s as an important longevity-relevant therapy with effects that exceed its original indication. The consumer effects are already surfacing in household spending data and financial reports across industries that may seem far removed from healthcare. Fully untangling GLP-1 impact from broader affordability pressures is difficult. But the impact should intensify as adoption continues to broaden. GLP-1s are likely an early example of a pattern that should recur with increasing frequency. As the convergence of AI and multiomics accelerates our understanding of biology and improves drug discovery and development, an increasing number of effective therapies targeting interconnected biological systems are likely to follow. Medicine is shifting from managing symptoms to treating the underlying biology of disease. For industries built around chronic disease — and the consumer behaviors that drive it — the consequences should compound. Read my full take in @ARKInvest's weekly newsletter. 👇